Loading...
Docoh

Verve Therapeutics (VERV)

News

From Benzinga Pro
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
10 May 22
Biotech, Earnings, M&A, News, Penny Stocks, Guidance, Health Care, Financing, Offerings, Small Cap, FDA, Management, Movers, Trading Ideas, General
Here's a roundup of top developments in the biotech space over the last 24 hours:
Verve Therapeutics Q1 EPS $(0.62) Up From $(4.99) YoY
10 May 22
Earnings, News
Verve Therapeutics (NASDAQ:VERV) reported quarterly losses of $(0.62) per share. This is a 87.58 percent increase over losses of $(4.99) per share from the same period last year.
Verve Therapeutics Reports Clearance Of First VERVE-101 Trial Application
10 May 22
Biotech, News, FDA, General
Verve on Track to Begin Dosing HeFH Patients in New Zealand in Mid-2022 in a Phase 1 Clinical Trial with Initial Clinical Data Expected in 2023 Preparing for Submission of United Kingdom and United States Regulatory
Verve Therapeutics Reports Additional VERVE-101 And GalNAc-Lipid Nanoparticle Delivery Data In Non-Human Primates At TIDES USA 2022
9 May 22
Biotech, News, FDA, General
VERVE-101 Preclinical Data Package Supports Company’s Global Development Strategy and Regulatory Submissions for Clinical Trials in Patients with HeFH Single Intravenous Infusion of VERVE-101 Clinical Formulation
Stocks That Hit 52-Week Lows On Friday
6 May 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Friday, 1043 companies hit new 52-week lows.
Stocks That Hit 52-Week Lows On Thursday
28 Apr 22
News, Options, Intraday Update, Markets
During Thursday, 849 stocks hit new 52-week lows.
Stocks That Hit 52-Week Lows On Wednesday
27 Apr 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
Wednesday's session saw 784 companies set new 52-week lows.
Stocks That Hit 52-Week Lows On Tuesday
26 Apr 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
During Tuesday, 581 stocks hit new 52-week lows. Interesting Highlights From Today's 52-Week Lows Meta Platforms (NASDAQ:FB) was the biggest company on a market cap basis to set a new 52-week low.
Stocks That Hit 52-Week Lows On Monday
25 Apr 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Monday, 721 companies achieved new lows for the year.
Stocks That Hit 52-Week Lows On Thursday
21 Apr 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Thursday, 236 companies hit new 52-week lows.
Stocks That Hit 52-Week Lows On Tuesday
19 Apr 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
On Tuesday, 242 companies hit new 52-week lows.
Verve Therapeutics Reports Durable And Well-tolerated Editing Of ANGPTL3 Gene Out To More Than 20 Months In Non-human Primates For Potential Treatment Of Atherosclerotic Cardiovascular Disease
4 Apr 22
Biotech, News, FDA, General
Verve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, reported updated preclinical data in non-human primates (NHPs)
68 Biggest Movers From Yesterday
16 Mar 22
News, Penny Stocks, Small Cap, Pre-Market Outlook, Markets, Movers, Trading Ideas
Gainers Sonim Technologies, Inc. (NASDAQ: SONM) shares jumped 103.3% to settle at $1.22 on Tuesday after the company announced its XP8 smartphone has integrated with the Walkie Talkie in Microsoft Teams.
Stocks That Hit 52-Week Lows On Tuesday
15 Mar 22
News, Options, Intraday Update, Markets, Movers, Trading Ideas
During Tuesday's session, 454 stocks hit new 52-week lows.
38 Stocks Moving In Tuesday's Mid-Day Session
15 Mar 22
News, Penny Stocks, Small Cap, Intraday Update, Markets, Movers, Trading Ideas
Gainers

Press releases

From Benzinga Pro
Verve Therapeutics Announces Clearance of First VERVE-101 Clinical Trial Application and Outlines Global Clinical Development Strategy; Reports First Quarter 2022 Financial Results
10 May 22
Earnings, Press Releases
Verve on Track to Begin Dosing HeFH Patients in New Zealand in Mid-2022 in a Phase 1 Clinical Trial with Initial Clinical Data Expected in 2023 Preparing for Submission of United Kingdom and United States
Verve Therapeutics Reports Additional VERVE-101 and GalNAc-Lipid Nanoparticle Delivery Data in Non-Human Primates at TIDES USA 2022
9 May 22
News, Health Care, Press Releases
VERVE-101 Preclinical Data Package Supports Company's Global Development Strategy and Regulatory Submissions for Clinical Trials in Patients with HeFH Single Intravenous Infusion of VERVE-101 Clinical Formulation Led to
Verve Therapeutics to Participate in Upcoming May Investor Conferences
4 May 22
Press Releases
CAMBRIDGE, Mass., May 04, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, announced that
Verve Therapeutics Presents Comprehensive Analyses of Off-target Editing Risk for VERVE-101 at Precision Genome Engineering Keystone Symposia
26 Apr 22
News, Press Releases
Extensive Analyses in Multiple Human Cell Types Demonstrate Minimal to No Off-target Editing Following VERVE-101 Treatment, Supporting its Planned Clinical Initiation in 2022 Whole Genome Sequencing at 500X Coverage of
Verve Therapeutics Reports Durable and Well-Tolerated Editing of ANGPTL3 Gene Out to More than 20 Months in Non-Human Primates for Potential Treatment of Atherosclerotic Cardiovascular Disease
4 Apr 22
Press Releases, General
Updated Sequential Dosing Data Show Administration of PCSK9 Base Editor Followed by ANGPTL3 Base Editor is Well-Tolerated in NHPs Data to be Presented Today at the American College of Cardiology 71st Annual Scientific
Verve Therapeutics to Participate in the Guggenheim Genomic Medicines and Rare Disease Conference
24 Mar 22
News, Press Releases
CAMBRIDGE, Mass., March 24, 2022 (GLOBE NEWSWIRE) -- Verve Therapeutics, a biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing medicines, today
Verve Therapeutics Announces Pipeline Progress and Reports Fourth Quarter and Full Year 2021 Financial Results
14 Mar 22
Earnings, Press Releases
Significant Progress Anticipated in 2022 with Initiation of Clinical Trial for VERVE-101 and IND-enabling Studies for ANGPTL3 Program Presentations at Upcoming Scientific Conferences to Highlight Novel Base Editing